Puslapis 1 nuo 131 rezultatus
Biodegradable Poly(L-lactic acid) microspheres containing neutron-activable 165Ho were designed for internal radiation therapy of hepatic tumors. Spheres composed of Poly(L-lactic acid) (PLA) were prepared with excellent reproducibility containing up to 36% of a holmium complex. The prepared spheres
Pancreatic cancer (PC) is one of the most difficult cancers to treat. Since the current chemotherapy is inadequate and various biological approaches have failed, the need for agents that have a potential to treat PC is pressing. Phospho-valproic acid (P-V), a novel anticancer agent, is efficacious
Colon cancer is one of the major causes of death in the Western world. Early detection significantly improves long-term survival for patients with colon cancer. Near-infrared (NIR) fluorescent nanoparticles are promising candidates for use as contrast agents for tumor detection. Using NIR offers
OBJECTIVE
The purpose of this study was to develop an active targeting strategy to improve the therapeutic antitumor efficacy of oridonin (ORI), the main active ingredient in the medicinal herb Rabdosia rubescens.
METHODS
A modified spontaneous emulsification solvent diffusion method was used to
A drug-loaded implantable scaffold is a promising alternative for the treatment of a tissue defect after tumor resection. In this study, mesoporous silica nanoparticles (MSNs) were used as carriers to load an anticancer drug - doxorubicin hydrochloride (DOX), and the DOX-loaded MSNs (DOX@MSNs) were
Polymeric micelles were constructed from poly(l-lactic acid) (PLA; M(n) 3K)-b-poly(ethylene glycol) (PEG; M(n) 2K)-b-poly(l-histidine) (polyHis; M(n) 5K) as a tumor pH-specific anticancer drug carrier. Micelles (particle diameter: approximately 80 nm; critical micelle concentration (CMC): 2
BACKGROUND
Intra-arterial embolization of unresectable malignant tumours with biodegradable microspheres is an effective way of selective anti-tumour therapy. Promising candidates are Dextran hydrogel (Dex) microspheres for chemo-embolization and Holmium-166 poly(L-lactic acid) (166HoPLA)
Despite advances in polymeric nanoparticles (NPs) as effective delivery systems for anticancer drugs, rapid clearance from blood and poor penetration capacity in heterogeneous tumors still remain to be addressed. Here, a dual coating of poly (ethylene glycol)-poly (d,l-lactic acid) (PEG-PDLLA) and
Cellulose based carriers have the potential for sustained release of drugs, which can protect drugs and deliver them to the target site. Herein, BA-loaded cellulose-graft-poly(l-lactic acid) nanoparticles (CE-g-PLLA/BA NPs) were fabricated by employing cellulose (CE) and poly(l-lactic acid) (PLLA)
A nanocarrier, lactosome, which is composed of poly(L-lactic acid)-block-poly(sarcosine), as a contrast agent for the liver tumor imaging was examined using the near infrared fluorescence (NIRF) optical imaging technique. Lactosome labeled with indocyanine green (ICG) showed a high escape ability
In order to produce biodegradable thermo-sensitive nanoparticles, alternating multi-block copolymers (MBC) were synthesized by coupling dicarboxylated poly(ethylene glycol) (PEG; M(w) 2000) with poly(L-lactic acid) (PLLA)/PEG/PLLA triblock copolymers. Three different multi-block copolymers were
Hepatic carcinoma (HCC) is one of the most common cancer and its treatment has been considered a therapeutic challenge. Doxorubicin (Dox) is one of the most important chemotherapeutic agents used in the treatment for liver cancer. However, the efficacy of Dox therapy is restricted by the
The physicochemical properties and in vivo distribution of poly(L-lactide) (L-PLA) microspheres containing 5-fluorouracil (5-FU) prepared by a solvent evaporation method were evaluated for potential use in the treatment of liver cancers. Two different molecular weight polymers of L-PLA [L-PLA1
Subsequently to the publication of the aobve article, the authors have realized that they overlooked including a 'Competing Interests' section. This should have been included in the paper as follows: 'GM, RW and GGM declare they have no competing interests. BR has an equity position in Medicon
β-Lapachone (LPC) is a novel cytotoxic agent that is bioactivated by NADP(H): quinone oxidoreductase 1 (NQO1), an enzyme elevated in a variety of tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer, liver cancer, and breast cancer. Despite its unique mechanism of action, its